CFA
ORMP icon

Carroll Financial Associates’s Oramed Pharmaceuticals ORMP Stock Holding History

Carroll Financial Associates’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$14K Sell
1,000
-1,000
-50% -$20.9K ﹤0.01% 1073
2021
Q3 		$43K Buy
+2,000
New +$34.1K ﹤0.01% 785

Other funds holding ORMP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Carroll Financial Associates's ORMP Position: Q4 2021 in Review

Carroll Financial Associates reduced its Oramed Pharmaceuticals (ORMP) stake by 50% in Q4 2021, selling an estimated $20.9K and leaving 1,000 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #1073.

Carroll Financial Associates first reported a position in ORMP in Q3 2021 and has held it in 2 quarters since. The position peaked at $43K in Q3 2021. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

  • Carroll Financial Associates held 1,000 shares of Oramed Pharmaceuticals worth $14K as of Q4 2021.
  • Carroll Financial Associates sold 1,000 Oramed Pharmaceuticals shares in Q4 2021, an estimated $20.9K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1073 holding.
  • Carroll Financial Associates first reported a position in Oramed Pharmaceuticals in Q3 2021 and has held it in 2 quarters since.
  • Carroll Financial Associates's Oramed Pharmaceuticals position peaked at $43K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.